Business Wire

IDEMIA

27.4.2020 03:02:08 CEST | Business Wire | Press release

Share
IDEMIA Provides Seamless Biometric Access Control to Digital Garage’s New Headquarters in Japan

IDEMIA, the global leader in Augmented Identity, today announced the first deployment of MorphoWave ™ Compact in Japan to provide high security and convenience for businesses and the public.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200426005034/en/

The contactless fingerprint technology was installed in the new headquarters of Digital Garage, located in the famous Shibuya district in Tokyo. They are the first to experience such a fast, frictionless and seamless biometric access control in Japan, through this deployment conducted in collaboration with IDEMIA’s official value added partner JAPAN AEROSPACE CORPORATION (JAC). JAC also conducted the network configuration using MorphoWave ™ Compact to integrate with Digital Garage’s system.

The Shibuya headquarters’ 450 employees enjoy all the benefits of MorphoWave ™ Compact for office and floor access control. They can authenticate their biometrics by a touchless “wave” gesture of the hand within the MorphoWave ™ Compact reader, which ensures efficiency, convenience, speed and security. This is also a more hygienic verification method since the users’ fingers are not in contact with the biometric sensor, whether accessing the building and floor or being enrolled.

MorphoWave ™ Compact is a biometric reader equipped with 3D fingerprint technology powered by Artificial Intelligence (AI) that can scan four fingers in less than one second. The algorithms in the biometric system ensure high matching accuracy and it enables up to 100,000 users being identified by one device. In a broader view, MorphoWave ™ Compact eliminates the need for cards, remembering PINs, tailgating and importantly, the concern of multiple people touching a surface.

Nezu Nobuyoshi, Managing Director and Vice President of Sales in IDEMIA Japan said: “With the increasing number of access points in buildings and offices, having touchless 3D fingerprint authentication technology is increasingly important to achieve convenience and maximum security. As a leader in biometrics, we want to provide entities with an advanced biometric technology that is convenient to use and allows users to identify themselves without complications.”

A spokesperson from Digital Garage said: “We are proud to be the first in Japan to implement this touchless 3D fingerprint technology for biometric access control, which ensures accurate identification of our employees and visitors. IDEMIA’s technology is the ideal fit for us, thanks to its versatile and easy deployment, accuracy and reliability in fingerprint matching.”

-END-

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With 13,000 employees around the world, IDEMIA serves clients in 180 countries.

For further information, go to www.idemia.com / And follow @IdemiaGroup on Twitter

About Digital Garage

Digital Garage is engaged in two recurring businesses: the fintech business, which provides a package of various payment methods to e-commerce operators and face-to-face retailers, and the marketing business, which provides integrated solutions in the digital and real fields. In addition, it is developing investment and development businesses for promising companies around the world. In addition, in collaboration with our core partners, they operate DG Lab, an open innovation R&D organization. As a company that creates new "contexts" in the Internet age, they will connect various businesses and create innovative services.

About JAC

JAPAN AEROSPACE CORPORATION (JAC) has a history of more than 60 years and a core aerospace company of ITOCHU Group, providing unique and specialized services based on the concept of "only one" and "niche top". JAC offers value added "engineering and technical” services and propose business solutions, mainly relating to national security and social infrastructure along with improvement of safety, comfortability and affordability to the Japanese market.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye